Medulloblastoma is the most common central nervous system tumor in children, while it is extremely rare in adults. Multimodal treatment involving surgery, radiotherapy and chemotherapy can improve the prognosis of this disease, and recent advances in molecular biology have allowed the identification of molecular subgroups (WNT, SHH, Groups 3 and 4), each of which have different cytogenetic, mutational and gene expression signatures, demographics, histology and prognosis. The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease.
Brandes, A.A., Bartolotti, M., Marucci, G., Ghimenton, C., Agati, R., Fioravanti, A., et al. (2015). New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 94(3), 348-359 [10.1016/j.critrevonc.2014.12.016].
New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology
DE BIASE, DARIO;TALLINI, GIOVANNI;
2015
Abstract
Medulloblastoma is the most common central nervous system tumor in children, while it is extremely rare in adults. Multimodal treatment involving surgery, radiotherapy and chemotherapy can improve the prognosis of this disease, and recent advances in molecular biology have allowed the identification of molecular subgroups (WNT, SHH, Groups 3 and 4), each of which have different cytogenetic, mutational and gene expression signatures, demographics, histology and prognosis. The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
